-
- 脂質ナノ粒子
Apr 17, 2025Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery -
- Expression Vector
Apr 07, 2025The host-vector system developed jointly with Fuso Pharmaceutical Industries, Ltd. has been commercialized by the company. -
- COVID-19
Apr 01, 2025Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. has submitted a rolling submission to the U.S. Food and Drug Administration (FDA) for Xocova as a prevention measure against COVID-19. -
- COVID-19
Mar 27, 2025Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. submitted an application in Japan for an additional indication of new coronavirus treatment Xocova for the prevention of COVID-19. -
- COVID-19
Jan 22, 2025Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. received approval for a new drug application in Taiwan and signed a government stockpiling agreement -
- SARS-CoV-2
Oct 15, 2024Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1. -
- SARS-CoV-2
Feb 16, 2024Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant -
- SARS-CoV-2
Jan 16, 2024Rational in silico design identifies two mutations that restore UT28K SARS-CoV-2 monoclonal antibody activity against Omicron BA.1 -
- SARS-CoV-2
Dec 19, 2023Viral uptake and pathophysiology of the lung endothelial cells in age-associated severe SARS-CoV-2 infection models -
- flavivirus
Nov 14, 2023Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain -
- SARS-CoV-2
Oct 17, 20232-thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses -
- PD-L1
Oct 05, 2023Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
